It's easy to look at Mistral AI's success and feel a jolt of optimism, like catching a glimpse of a hero in a movie, but one character's arc doesn't tell the whole story for everyone else in the scene.
Most startups are still in the struggle phase, trying to find their footing in the regulatory landscape where the path isn't clear or easy.
It's a bit like assuming every aspiring musician will fill arenas because Taylor Swift did; the stakes are high, but the conditions for success are rarely universal.
Until we see a clear, repeatable process for many companies, not just a few exceptional ones, the compatibility of AI regulation and investment remains a conditional promise, not a given reality for the general public.
For example, a small team in Montréal trying to get their AI medical diagnostic tool approved faces a very different journey than a well-funded, high-profile firm.